Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
Phase 2
54
about 1.7 years
18+
137 sites in CA, FL, GA +26
What this study is about
Researchers are testing whether adding enasidenib to the usual treatment of cedazuridine-decitabine improves outcomes in people with higher-risk myelodysplastic syndrome (MDS) that has an IDH2 mutation. The trial will compare this new combination therapy to the standard treatment, and it will last for about 627 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Decitabine and Cedazuridine
- 2.Take Enasidenib
- 3.Undergo Biospecimen Collection
- +2 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
decitabine, enasidenib
injection, intravenous, oral (Oral Tablet)
Primary: Complete response (CR) rate
Secondary: Duration of response, Event-free survival (EFS), Incidence of adverse events, Overall survival (OS), Time to response
diagnostic, biopsy